| 000 | 00963 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250513154254.0 | ||
| 264 | 0 | _c19990129 | |
| 008 | 199901s 0 0 eng d | ||
| 022 | _a0114-5916 | ||
| 024 | 7 |
_a10.2165/00002018-199819040-00004 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHawkridge, S M | |
| 245 | 0 | 0 |
_aA risk-benefit assessment of pharmacotherapy for anxiety disorders in children and adolescents. _h[electronic resource] |
| 260 |
_bDrug safety _cOct 1998 |
||
| 300 |
_a283-97 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 |
_aAnti-Anxiety Agents _xadverse effects |
| 650 | 0 | 4 |
_aAnxiety Disorders _xdrug therapy |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aHumans |
| 700 | 1 | _aStein, D J | |
| 773 | 0 |
_tDrug safety _gvol. 19 _gno. 4 _gp. 283-97 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2165/00002018-199819040-00004 _zAvailable from publisher's website |
| 999 |
_c9768799 _d9768799 |
||